IL311106A - Solid forms of BCL-2 inhibitors, their method of preparation and use - Google Patents

Solid forms of BCL-2 inhibitors, their method of preparation and use

Info

Publication number
IL311106A
IL311106A IL311106A IL31110624A IL311106A IL 311106 A IL311106 A IL 311106A IL 311106 A IL311106 A IL 311106A IL 31110624 A IL31110624 A IL 31110624A IL 311106 A IL311106 A IL 311106A
Authority
IL
Israel
Prior art keywords
bcl
inhibitors
preparation
solid forms
solid
Prior art date
Application number
IL311106A
Other languages
English (en)
Hebrew (he)
Original Assignee
Beigene Ltd
Beigene Switzerland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd, Beigene Switzerland Gmbh filed Critical Beigene Ltd
Publication of IL311106A publication Critical patent/IL311106A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL311106A 2021-08-31 2022-08-31 Solid forms of BCL-2 inhibitors, their method of preparation and use IL311106A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021115718 2021-08-31
PCT/CN2022/116084 WO2023030363A1 (en) 2021-08-31 2022-08-31 Solid forms of bcl-2 inhibitors, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
IL311106A true IL311106A (en) 2024-04-01

Family

ID=85410866

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311106A IL311106A (en) 2021-08-31 2022-08-31 Solid forms of BCL-2 inhibitors, their method of preparation and use

Country Status (11)

Country Link
US (1) US20240317743A1 (https=)
EP (1) EP4396180A4 (https=)
JP (1) JP2024530315A (https=)
KR (1) KR20240054327A (https=)
CN (1) CN118215660A (https=)
AU (1) AU2022336557A1 (https=)
CA (1) CA3230314A1 (https=)
IL (1) IL311106A (https=)
MX (1) MX2024002465A (https=)
TW (1) TW202328125A (https=)
WO (1) WO2023030363A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
WO2026002056A1 (en) 2024-06-26 2026-01-02 Beone Pharmaceutical (Suzhou) Co., Ltd. A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138588A2 (en) * 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2668180B1 (en) * 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
SG11202009933WA (en) * 2018-04-29 2020-11-27 Beigene Ltd Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Also Published As

Publication number Publication date
JP2024530315A (ja) 2024-08-16
WO2023030363A1 (en) 2023-03-09
CA3230314A1 (en) 2023-03-09
KR20240054327A (ko) 2024-04-25
CN118215660A (zh) 2024-06-18
AU2022336557A1 (en) 2024-03-21
EP4396180A4 (en) 2025-07-09
TW202328125A (zh) 2023-07-16
EP4396180A1 (en) 2024-07-10
US20240317743A1 (en) 2024-09-26
MX2024002465A (es) 2024-04-29

Similar Documents

Publication Publication Date Title
PT3911648T (pt) 6¿-[[(1s,3s)-3-[[5-(difluorometoxi)-2-pirimidinil]amino]ciclopentil]amino][1(2h),3¿-bipiridina]-2-ona como inibidor de pcsk9 e seus métodos de utilização
SG11202107615TA (en) Pcsk9 inhibitors and methods of use thereof
ZA202202932B (en) Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
IL278036A (en) 1HPK inhibitors, method of preparation and administration
IL287973A (en) acss2 inhibitors and methods of their use
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
GB2600569B (en) Device Coupon and Method of Manufacture thereof
EP4033440A4 (en) BLOCKCHAIN CONSENSUS METHOD, APPARATUS AND DEVICE
EP3986894A4 (en) ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
IL264854A (en) Spt5 inhibitors and methods of use thereof
IL287293A (en) RNA editing inhibitors and methods of use
IL311106A (en) Solid forms of BCL-2 inhibitors, their method of preparation and use
SG11202106998TA (en) Strains, composition and method of use
EP3959197A4 (en) PAPD5 INHIBITORS AND METHODS OF USE THEREOF
GB202010768D0 (en) Cable-tidy apparatus, and method of use thereof
IL289586A (en) pi4kiii alpha micromolecule inhibiting preparation, method for its preparation and use
ZA202107810B (en) Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof
IL304719A (en) Methods for preparing scrapomes and their uses
EP4100005A4 (en) ADAMTS INHIBITORS, METHODS OF MANUFACTURE AND MEDICAL USES THEREOF
IL308157A (en) Antibodies against TIGIT, antibodies against CD96, and methods of using them
EP4172050A4 (en) CUPS AND METHOD OF USE
HK40106233A (en) Solid forms of bcl-2 inhibitors, method of preparation, and use thereof
IL313623A (en) Solid forms of TYK2 inhibitor, method for their preparation and use
IL314293A (en) Olanzapine, its compounds and methods of using it
GB2595948B (en) Coupon wafer and method of preparation thereof